Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 3
Abstract
AR-42, a new orally bioavailable, potent, hydroxamate-tethered phenylbutyrate class I/IIB histone deacetylase inhibitor currently is under evaluation in phase 1 and 2 clinical trials and has demonstrated activity in both hematologic and solid tumor malignancies. This report focuses on the preclinical characterization of the pharmacokinetics of AR-42 in mice and rats. A high-performance liquid chromatography–tandem mass spectrometry assay has been developed and applied to the pharmacokinetic study of the more active stereoisomer, S-AR-42, when administered via intravenous and oral routes in rodents, including plasma, bone marrow, and spleen pharmacokinetics (PK) in CD2F1 mice and plasma PK in F344 rats. Oral bioavailability was estimated to be 26 and 100% in mice and rats, respectively. R-AR-42 was also evaluated intravenously in rats and was shown to display different pharmacokinetics with a much shorter terminal half-life compared to that of S-AR-42. Renal clearance was a minor elimination pathway for parental S-AR-42. Oral administration of S-AR-42 to tumor-bearing mice demonstrated high uptake and exposure of the parent drug in the lymphoid tissues, spleen, and bone marrow. This is the first report of the pharmacokinetics of this novel agent, which is now in early phase clinical trials.
Authors and Affiliations
Hao Cheng, Zhiliang Xie, William P. Jones, Xiaohui Tracey Wei, Zhongfa Liu, Dasheng Wang, Samuel K. Kulp, Jiang Wang, Christopher C. Coss, Ching-Shih Chen, Guido Marcucci, Ramiro Garzon, Joseph M. Covey, Mitch A. Phelps, Kenneth K. Chan
Keywords
Related Articles
- EP ID EP680881
- DOI 10.1208/s12248-016-9876-3
- Views 56
- Downloads 0
Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites
The online version of this article (doi:10.1208/s12248-012-9443-5) contains supplementary material, which is available to authorized users.
Handling Data Below the Limit of Quantification in Mixed Effect Models
The purpose of this study is to investigate the impact of observations below the limit of quantification (BQL) occurring in three distinctly different ways and assess the best method for prevention of bias in parameter e...
The Use of Biorelevant Dissolution Media to Forecast the In Vivo Performance of a Drug
Simulation of gastrointestinal conditions is essential to adequately predict the in vivo behavior of drug formulations. To reduce the size and number of human studies required to identify a drug product with appropriate...
DNA-based therapeutics and DNA delivery systems: A comprehensive review
The past several years have witnessed the evolution of gene medicine from an experimental technology into a viable strategy for developing therapeutics for a wide range of human disorders. Numerous prototype DNA-based bi...
Chemical Potency and Degradation Products of Medications Stored Over 550 Earth Days at the International Space Station
The online version of this article (doi:10.1208/s12248-015-9834-5) contains supplementary material, which is available to authorized users.